Last week's FDA panel nod for Cardiome Pharma Corp.'s intravenous atrial fibrillation/flutter drug vernakalant - lately branded Kynapid - came with the expected provisos, and put the company in strong position as the race to market continues for I.V. and oral versions of AF drugs. (BioWorld Financial Watch) Read More
